Crestmont Private Wealth LLC Lowers Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Crestmont Private Wealth LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.9% in the fourth quarter, Holdings Channel reports. The firm owned 3,546 shares of the biopharmaceutical company’s stock after selling 621 shares during the period. Crestmont Private Wealth LLC’s holdings in Gilead Sciences were worth $328,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in GILD. Accurate Wealth Management LLC raised its holdings in shares of Gilead Sciences by 7.1% in the fourth quarter. Accurate Wealth Management LLC now owns 3,456 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 230 shares in the last quarter. 180 Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 81.1% in the fourth quarter. 180 Wealth Advisors LLC now owns 10,990 shares of the biopharmaceutical company’s stock valued at $1,015,000 after acquiring an additional 4,920 shares in the last quarter. Global Financial Private Client LLC raised its holdings in shares of Gilead Sciences by 1,222.0% in the fourth quarter. Global Financial Private Client LLC now owns 6,068 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 5,609 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $471,000. Finally, First Financial Corp IN bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $68,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $91.00 on Wednesday. The business’s 50 day moving average price is $91.96 and its 200 day moving average price is $83.69. The firm has a market cap of $113.41 billion, a P/E ratio of 1,011.11, a P/E/G ratio of 2.24 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the prior year, the firm posted $2.29 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.38%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Mizuho lifted their price objective on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price for the company. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Truist Financial boosted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Finally, Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 453,734 shares of company stock worth $41,902,086. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.